<DOC>
	<DOC>NCT00382668</DOC>
	<brief_summary>The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.</brief_summary>
	<brief_title>A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Inclusion Criteria All subjects: Male and females â‰¥18 years old Women must be of nonchildbearing potential Adequate hematologic and renal function BMI 1835 kg/m2 Inclusion Criteria Liver Impaired subjects: Subjects must have stable liver impairment diagnosed with standard classification Child Pugh Exclusion Criteria All subjects: Inability to swallow or absorb oral medication Uncontrolled medical disorder or infection Use of CYP3A4 inhibitors/inducers or drugs with risk of Torsades de Pointes Uncontrolled or Significant cardiovascular disease Any significant bleeding disorder Female subjects of childbearing potential Male subjects unwilling to use an effective method of contraception throughout the conduct of the study and for 2 months thereafter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>hepatically impaired</keyword>
</DOC>